Clinical trial
Usefulness of Tumor Heterogeneity Assessment in Patients With MCRPC Undergoing Radioligand Therapy With 177LU-PSMA-617 Using Serial 18F-DCFPYL, 18F-FDG and 18F-Fluciclovine PET/CT Predicting Clinical Outcome
NCT06706921 is registered in ClinicalTrials.gov with VA Greater Los Angeles Healthcare System as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Usefulness of Tumor Heterogeneity Assessment in Patients With MCRPC Undergoing Radioligand Therapy With 177LU-PSMA-617 Using Serial 18F-DCFPYL, 18F-FDG and 18F-Fluciclovine PET/CT Predicting Clinical Outcome
- Lead sponsor
- VA Greater Los Angeles Healthcare System
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- December 15, 2024
- Completion date
- November 1, 2027
- Enrollment
- 15 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
genital diseases, male, genital neoplasms, male, male urogenital diseases, metastatic prostate cancer, neoplasms, neoplasms by site, prostatic diseases, prostatic neoplasms, prostatic neoplasms, castration-resistant, urogenital diseases, male, urogenital neoplasms